Ultragenyx Pharmaceuticals looks to cut costs following the trial failure, while attention remains squared on its burgeoning commercial business.
Yahoo
Skip to navigation
Skip to main content
Skip to right column
Ultragenyx Drug Fails Trial. 2 Reasons the Stock Could Bounce Back From 44% Drop. ·
Barrons.com
·
Dreamstime
